Abstract The National Alzheimer's Project Act identifies the effective treatment and
prevention of Alzheimer's by 2025 as an urgent public health mission. This priority is …

Clinical Alzheimer's disease (AD) trials currently face a critical shortfall of thousands of
eligible participants, which inflates the duration and cost of the clinical study as well as …

Importance Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD)
clinical trials limits generalizability of results and hinders opportunities to examine potential …

Randomized clinical trials (RCT) involve labor-intensive, highly regulated, and controlled
processes intended to transform scientific concepts into clinical outcomes. To be effective …

In the search for treatments to delay or halt the progression of Alzheimer disease (AD),
researchers see promise in clinical trials that enroll people without cognitive decline who …

The 2012 National Plan to Address Alzheimer's Disease set an ambitious goal: to both
prevent and effectively treat Alzheimer's disease by 2025. To reach this goal, tens of …

Personalized medicine aims to tailor diagnosis and treatment based on an individual's
personal genetic make-up and other predictive biomarkers—rather than a one-size fits all …

We describe the history, development, and success of the recruitment and screening
procedures used by researchers at the University of California, Davis Alzheimer's Disease …

The poor generalizability of clinical research data due to the enrollment of highly educated,
non‐Latinx White participants hampers the development of therapies for Alzheimer's …

The recruitment of asymptomatic volunteers has been identified as a critical factor that is
delaying the development and validation of preventive therapies for Alzheimer disease (AD) …